Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Endometrial cancer data on Genmab’s Elahere rival beat forecast
The biotech reported a 50% unconfirmed response rate, beating the expectations of analysts to boost confidence ahead of a move into phase 3.
Nick Paul Taylor
May 23, 2025 9:22am
Merus hails 'unprecedented' survival on solid tumor bispecific
May 23, 2025 7:35am
Innate says lymphoma data shows anti-KIR3DL2 antibody’s promise
May 23, 2025 5:13am
ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC
May 22, 2025 5:00pm
After setback, Merck KGaA shows data justifying lupus ph. 3 push
May 21, 2025 9:50am
Accropeutics' TYK2/JAK1 inhibitor scores phase 2 psoriasis win
May 21, 2025 6:25am
